Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Ventricular arrhythmias after atrial fibrillation electrical cardioversion: A multicenter study

O. Tovia-Brodie, Y. Michowitz, F. Bayya, S. Havranek, M. Dusik, L. Rivetti, R. Mantovan, A. Sabbag, E. Massalha, PE. Lazzerini, I. Bertolozzi, G. Malanchini, CT. Witt, Ó. Cano, Z. Dadon, M. Ilan, PG. Postema, M. Glikson, M. Rav Acha

. 2024 ; 5 (11) : 813-820. [pub] 20240827

Status neindexováno Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25002219

BACKGROUND: Ventricular arrhythmias (VAs) after atrial fibrillation (AF) electrical cardioversion (ECV) have been reported. OBJECTIVE: We sought to assess incidence, timing, and clinical characteristics of patients with post-AF ECV-related VAs. METHODS: Multicenter observational retrospective study including 13 centers, incorporating patients with VAs or sudden cardiac death within 10 days of ECV. The total number of ECVs performed during the collecting period was provided. Patients with pre-ECV VAs were excluded. RESULTS: Twenty-three patients with VAs were identified out of 11,897 AF ECVs performed in 13 centers during a median 2-year period, suggesting post-ECV VA incidence of 0.2%. The patients' mean age was 71 ± 11 years, and 13 (56.5%) were female. AF duration prior to ECV was 71 ± 54 days. Congestive heart failure and hypertension were both found in 17 (74%) patients. QT-prolonging drugs were used by 17 (74%). Index VA occurred 28.5 (interquartile range 5.5-72) hours post-ECV, including torsades de pointes, nonsustained polymorphic ventricular tachycardia, and sudden cardiac death in 17 (74%), 5 (22%), and 1 (4%) patient, respectively. Post-ECV heart rate was slower and QT duration longer compared with pre-ECV (57 ± 11 beats/min vs 113 ± 270 beats/min; P < .001; QT duration 482 ± 61 ms vs 390 ± 60 ms; P < .001). VAs reoccurred in 9 (39%) patients, 11 (interquartile range 3-13.5) hours post-index VA. Two patients had an arrhythmic death within 72 hours post-ECV. CONCLUSION: VAs post-AF ECV are rare, occur within 3 to 72 hours post-ECV, and are potentially fatal. Our study gives a signal of caution favoring prolonged monitoring in small subset of patients as congestive heart failure patients treated with class III antiarrhythmic drugs, with post-ECV bradycardia, especially (but not exclusively) when QT prolongation noted.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002219
003      
CZ-PrNML
005      
20250123102017.0
007      
ta
008      
250117s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.hroo.2024.08.009 $2 doi
035    __
$a (PubMed)39651435
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Tovia-Brodie, Oholi $u Department of Cardiology, Jesselson Integrated Heart Center, Shaare Zedek Medical Center, Jerusalem, Israel $u Faculty of Medicine, Hebrew University, Jerusalem, Israel
245    10
$a Ventricular arrhythmias after atrial fibrillation electrical cardioversion: A multicenter study / $c O. Tovia-Brodie, Y. Michowitz, F. Bayya, S. Havranek, M. Dusik, L. Rivetti, R. Mantovan, A. Sabbag, E. Massalha, PE. Lazzerini, I. Bertolozzi, G. Malanchini, CT. Witt, Ó. Cano, Z. Dadon, M. Ilan, PG. Postema, M. Glikson, M. Rav Acha
520    9_
$a BACKGROUND: Ventricular arrhythmias (VAs) after atrial fibrillation (AF) electrical cardioversion (ECV) have been reported. OBJECTIVE: We sought to assess incidence, timing, and clinical characteristics of patients with post-AF ECV-related VAs. METHODS: Multicenter observational retrospective study including 13 centers, incorporating patients with VAs or sudden cardiac death within 10 days of ECV. The total number of ECVs performed during the collecting period was provided. Patients with pre-ECV VAs were excluded. RESULTS: Twenty-three patients with VAs were identified out of 11,897 AF ECVs performed in 13 centers during a median 2-year period, suggesting post-ECV VA incidence of 0.2%. The patients' mean age was 71 ± 11 years, and 13 (56.5%) were female. AF duration prior to ECV was 71 ± 54 days. Congestive heart failure and hypertension were both found in 17 (74%) patients. QT-prolonging drugs were used by 17 (74%). Index VA occurred 28.5 (interquartile range 5.5-72) hours post-ECV, including torsades de pointes, nonsustained polymorphic ventricular tachycardia, and sudden cardiac death in 17 (74%), 5 (22%), and 1 (4%) patient, respectively. Post-ECV heart rate was slower and QT duration longer compared with pre-ECV (57 ± 11 beats/min vs 113 ± 270 beats/min; P < .001; QT duration 482 ± 61 ms vs 390 ± 60 ms; P < .001). VAs reoccurred in 9 (39%) patients, 11 (interquartile range 3-13.5) hours post-index VA. Two patients had an arrhythmic death within 72 hours post-ECV. CONCLUSION: VAs post-AF ECV are rare, occur within 3 to 72 hours post-ECV, and are potentially fatal. Our study gives a signal of caution favoring prolonged monitoring in small subset of patients as congestive heart failure patients treated with class III antiarrhythmic drugs, with post-ECV bradycardia, especially (but not exclusively) when QT prolongation noted.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Michowitz, Yoav $u Department of Cardiology, Jesselson Integrated Heart Center, Shaare Zedek Medical Center, Jerusalem, Israel $u Faculty of Medicine, Hebrew University, Jerusalem, Israel
700    1_
$a Bayya, Feras $u Department of Cardiology, Jesselson Integrated Heart Center, Shaare Zedek Medical Center, Jerusalem, Israel $u Faculty of Medicine, Hebrew University, Jerusalem, Israel
700    1_
$a Havranek, Stepan $u Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia
700    1_
$a Dusik, Milan $u Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia
700    1_
$a Rivetti, Luigi $u Department of Cardiology, S. Maria dei Battuti Hospital, Conegliano, Italy
700    1_
$a Mantovan, Roberto $u Department of Cardiology, S. Maria dei Battuti Hospital, Conegliano, Italy
700    1_
$a Sabbag, Avi $u Department of Cardiology, Sheba Medical Center, Ramat Gan, Israel
700    1_
$a Massalha, Eyas $u Department of Cardiology, Sheba Medical Center, Ramat Gan, Israel
700    1_
$a Lazzerini, Pietro Enea $u Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy $u Electroimmunology Unit, Division of Internal Medicine and Geriatrics, University Hospital Le Scotte, Siena, Italy
700    1_
$a Bertolozzi, Iacopo $u Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy $u Department of Cardiology, San Giovanni of God Hospital, Florence, Italy
700    1_
$a Malanchini, Giovanni $u Department of Cardiology, ASST Papa Giovanni XXIII Bergamo, Bergamo, Italy
700    1_
$a Witt, Christoffer Tobias $u Department of Cardiology, Aarhus University Hospital, Aahrhus, Denmark
700    1_
$a Cano, Óscar $u Department of Cardiology, Hospital Universitario y Politecnico La Fe, Valencia, Spain
700    1_
$a Dadon, Ziv $u Department of Cardiology, Jesselson Integrated Heart Center, Shaare Zedek Medical Center, Jerusalem, Israel $u Faculty of Medicine, Hebrew University, Jerusalem, Israel
700    1_
$a Ilan, Michael $u Department of Cardiology, Jesselson Integrated Heart Center, Shaare Zedek Medical Center, Jerusalem, Israel $u Faculty of Medicine, Hebrew University, Jerusalem, Israel
700    1_
$a Postema, Pieter G $u Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
700    1_
$a Glikson, Michael $u Department of Cardiology, Jesselson Integrated Heart Center, Shaare Zedek Medical Center, Jerusalem, Israel $u Faculty of Medicine, Hebrew University, Jerusalem, Israel
700    1_
$a Rav Acha, Moshe $u Department of Cardiology, Jesselson Integrated Heart Center, Shaare Zedek Medical Center, Jerusalem, Israel $u Faculty of Medicine, Hebrew University, Jerusalem, Israel
773    0_
$w MED00209104 $t Heart rhythm O2 $x 2666-5018 $g Roč. 5, č. 11 (2024), s. 813-820
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39651435 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250117 $b ABA008
991    __
$a 20250123102011 $b ABA008
999    __
$a ok $b bmc $g 2254505 $s 1238222
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 5 $c 11 $d 813-820 $e 20240827 $i 2666-5018 $m Heart rhythm O2 $n Heart Rhythm O2 $x MED00209104
LZP    __
$a Pubmed-20250117
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace